The Australia Research Council (ARC) has awarded a $370,000 Linkage grant to Paul Young, Daniela Traini, and Brian Oliver of RespiTech and the cell biology group at the Woolcock Institute of Medical Research (WIMR) for development of an aerosol anti-fibrotic for the treatment of pulmonary lung fibrosis. The team's research proposal was titled "A tight squeeze: … [Read more...] about RespiTech gets grant for inhaled pulmonary fibrosis treatment
Business
Kamada gets new patents for inhaled AAT
Israeli phamaceutical company Kamada Ltd announced that it has received Russian and Australian patents related to its inhaled alpha-1 antitrypsin (AAT) for the treatment of lung diseases. Russian Patent No. 2472524 is titled “Alpha-1 Antitrypsin for treating exacerbation episodes of pulmonary diseases,” and the Australian Patent, No. 2007213344, is titled “Pulmonary … [Read more...] about Kamada gets new patents for inhaled AAT
Civitas gets second grant for inhaled L-dopa from Michael J. Fox Foundation
Civitas Therapeutics has received a $1 million grant from The Michael J. Fox Foundation for Parkinson’s Research for development of CVT-301 inhaled L-dopa for the treatment of motor fluctuations in Parkinson's disease patients, the company said. The grant will support a Phase 2b trial of the carrier-free dry powder formulation. The foundation previously awarded … [Read more...] about Civitas gets second grant for inhaled L-dopa from Michael J. Fox Foundation
MicroDose Therapeutx acquired by Teva
Teva has announced that it will acquire inhaled drug developer MicroDose Therapeutx for $40 million up front plus up to $125 million in development and regulatory milestone payments, as well as sales milestone payments and royalties. Calling the acquisition "a significant step toward expanding its respiratory pipeline," the company cited MicroDose’s proprietary dry … [Read more...] about MicroDose Therapeutx acquired by Teva
Elan shareholders reject Theravance deal
Shareholders of Elan Corporation have rejected the company's $1 billion deal for royalties from Theravance inhaled drugs, including the Breo and Anoro Ellipta DPIs. Anticipating the result from the Theravance vote, Elan announced on June 14 that it would put itself up for sale. Theravance CEO Rick Winningham responded to the vote saying, "While we are disappointed … [Read more...] about Elan shareholders reject Theravance deal
Theravance deal in doubt, Elan board goes forward with sale process
So many shareholders have already voted against Elan's proposed $1 billion deal for royalties from Theravance inhaled drug products, says Royalty Pharma, that the proposal is unlikely to pass at the upcoming meeting of Elan shareholders on June 17. Without citing any reason, Elan's board has now announced that it will proceed with the sale of the company, saying that … [Read more...] about Theravance deal in doubt, Elan board goes forward with sale process
Pearl Therapeutics to be acquired by AstraZeneca
AstraZeneca has announced today that it will acquire 100% of the shares of inhaled drug developer Pearl Therapeutics for $560 million, plus up to $450 million in milestone payments and an additional $140 million if sales goals are met. Pearl announced the initiation of a Phase 3 program for its PT003 formoterol fumarate/glycopyrrolate MDI for the treatment of COPD in … [Read more...] about Pearl Therapeutics to be acquired by AstraZeneca
Biotie Therapies looks to acquire diazepam nasal spray
Finnish drug developer Biotie Therapies has announced that it is paying $1 million for an exclusive option to acquire Neurelis, Inc., which is developing NRL-1, an intranasal diazepam formulation for the treatment of epilepsy. The FDA cleared the IND for NRL-1 in February 2012. If Biotie exercises its option, it will pay $8.75 million for all outstanding shares of … [Read more...] about Biotie Therapies looks to acquire diazepam nasal spray
Rexam adds manufacturing capabilities
Device manufacturer Rexam Healthcare has announced a €20 million expansion of its manufacturing operations at its site in Le Tréport, France, giving the site a total workspace of 5200 sq m. Rexam will manufacture the new Advancia nasal spray pump and other drug delivery devices at Le Tréport. The company says that it plans to hire 50 new employees, bringing the total … [Read more...] about Rexam adds manufacturing capabilities
Meda and Cipla expand Dymista partnership; Meda denies talk of sale to Sun
Meda has announced an expansion in its partnership with Cipla, which is already supplying azelastine for Meda's Dymista nasal spray. With the new agreement, Meda will continue to take responsibility for clinical development and commercialization of Dymista; Cipla will take responsibility for formulation. According to Meda, the company will "now have full coverage in … [Read more...] about Meda and Cipla expand Dymista partnership; Meda denies talk of sale to Sun